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ABSTRACT: A series of N,N-diethyl-3-substituted-2-(4-methylphenylsulfonamido)alkanamides (8a-k) and their 
arylsulfonamide precursors (7a-k) have been synthesized via facile approach. The chemical structures of the synthesized 
compounds were confirmed by analytical data and spectroscopic means. The in vitro antibacterial screening of these 
compounds along with streptomycin, showed N,N-diethyl-2-(4-methylphenylsulfonamido) -3-phenylpropanamide (8j) to be 
the most active agent on Escherichia coli at MIC of 12.5 μg/mL and on Staphylococcus aureus at MIC of 25 μg/mL.    
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Introduction 
Sulfonamide compounds were the first antimicrobial drugs 
which paved way for the unprecedented revolution in the 
world of antibiotics in medicine.1 The first of such 
sulfonamides was actually a prodrug with the trade name 
Prontosil1. Since then, sulfonamides have continued to 
attract considerable attention in pharmaceutical 
development, because of their aqueous stability despite 
their net neutral charge2. Sulfonamides are among the most 
widely used antibacterial agents in the world, chiefly 
because of their low cost, low toxicity and excellent 
activity against common bacterial diseases3.   
The chemistry of sulfonamides has recently shown 
them to be highly efficient synthons in the preparation of 
various valuable biologically active compounds4,5. 
Although, many synthetic methods have been reported for 
the preparation of sulfonamides6-8, but sulfonylation of 
ammonia9 or primary and secondary amines with sulfonyl 
chlorides in the presence of a base is still being used as the 
method of choice because of high efficiency and simplicity 
of the reaction10. Sulfonamides are clinically important 
drugs in treating various gastrointestinal diseases and other 
forms of infections11. Apart from these, sulfonamides have 
also been reported to possess, among others, 
antibacterial12,13, anti-HIV14,15, antimalarial16,17, antitumor18,19, 
antiviral activity20.  
The mode of action of sulfonamide drug is based on the 
inhibition of DNA synthesis21 by interfering with para-
aminobenzoic acid (PABA) in biosynthesis of folic acid 
which is essential for growth of bacterial cells22. The 
sulfonamide group has been proven to have remarkable 
utility in medicinal chemistry and features in the structure 
of a number of clinically relevant small molecules23. For 
instance, some currently approved drugs with sulfonamide 
structural skeletons include; the antihypertensive agent 
bosentan 124, the antiviral HIV protease inhibitor 
amprenavir 225, the phophodiesterase-5 inhibitor sildenafil 
326, antidiabetic drug glibenclamide 427, antidiabetic 
nonantibiotic glimepiride 5 and the diuretic drug 
torasemide 628. 
Epidemiological studies have revealed that emergence 
of new diseases is at the alarming rates in the recent time 
and that drug resistance is fasting becoming unbearable 
predicament in antimicrobial drug administration29. 
Methicillin-resistant staphylococci are resistant to many 
antibiotics such as penicillin, carbapenems, cephems and 
beta-lactam, quinolone, amino glycosides and 
tetracycline30-32, whereas sulfonamides and their 
combination therapies are gaining more attention by the 
day in antimicrobial drug research33. Thus, it is conceivable 
to develop a series of functionalized sulfonamides with 
dialkylated amide side chain modification on carboxyl 
functionality for possible antibacterial efficacy. 
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Fig. 1 Some important sulfonamide-based drugs available in market. 
Results and Discussion 
Chemistry 
Arylsulfonamides of the type, p-toluenesulfonamides were 
successful prepared by condensation reaction of p-
toluenesulfonyl chloride (p-TsCl) with various cheap and 
readily available amino acids in basified condition 
according to a known procedure with slight modification 
(Scheme 1). Although, some of these p-
toluenesulfonamides have been reported before; however, 
slight modification of a known procedure34 used in this 
study gave allowance for reaction augmentation and yield 
improvement. In addition, the in vitro antibacterial activity 
of these compounds on Escherichia coli and 
Staphylococcus aureus has not been investigated to our 
knowledge. In detail, the treatment of p-TsCl with 
equimolar quantity of 10 different amino acids afforded ten 
p-toluene sulfonamides (7a-j) while its reaction with half 
molar equivalent of tyrosine gave (7k) (Scheme 1). The 
coupling was achieved by adding p-TsCl to appropriate 
amino acid in aqueous sodium carbonate in three portions 
over a period of 1 h. The resulting solution was stirred at 
room temperature (RT) for 4 h and worked-up by 
acidification to pH 2.2 to afford p-toluenesulfonamides 
(7a-k) in good to excellent yields (60.5 – 99.0%). 
Furthermore, formation of the amide bond has been one 
of the most widely studied reactions in organic chemistry 
because of its importance in biological systems. In view of 
this, we envisaged that incorporation of amide template 
within the sulfonamide scaffold may lead to increase in 
antibacterial activity. Another motivation behind synthesis 
of (8a-k) was based on the earlier report that disubstituted 
amides are more biologically active than the non-
substituted counterparts35. Therefore, incorporation of 
amide group into the p-toulenesulfonamide was carried out 
in order to vary the antibacterial activity of such templates. 
This was achieved by the synthetic modification of the 
carboxyl side chain of the p-toluenesulfonamides (7a-k) 
via non-conventional amidation approach to afford N,N-
diethyl substituted amido scaffolds (8a-k) (Table 1). 
Contrary to the conventional method of generating the acid 
chloride used in the earlier report36, we have herein used 
Swern oxidation related approach which facilitated the 
synthesis of targeted N,N-diethyl amidated p-
toluenesulfonamide in one pot two steps protocol37. This 
route does not require any purification step and the target 
compound precipitated from the reaction mixture, 
simplifying its handling and isolation in good yields. 
According to spectral study, the structures of 
compounds (7a-k) as well as their N,N-diethyl amide 
bearing counterparts (8a-k) were deduced from their 
elemental analyses, as well as IR, high-field 1H- and 13C-
NMR, and mass spectra. The results of the data were in 
agreement with the proposed structures. Synthetic 
conversion of p-toluenesulfonamide to N,N-diethyl amide 
derivatives was monitored spectroscopically using 
conversion of 3-methyl-2-(4-methylphenylsulfonamido) 
butanoic acid (7g) to N,N-diethyl-3-methyl-2-(4-methyl-
phenylsulfonamido) butanamide (8g) as the representative 
template. The 1H-NMR of (7g) showed two aromatic 
protons at δ 7.73-7.71 and 7.29-7.27 each while NH proton 
resonated as a doublet at δ 5.07-5.04. The signal at δ 2.41 
was as a result of 3H of CH3-Ph while the remaining two 
CH3 protons resonated up-field as doublets at δ 0.97-0.96 
and 0.88-0.86. On the other hand, (8g) showed three 
additional signals in its 1H-NMR which were not present in 
(7g). This signals were 4H multiplet at 3.15-3.02 (2 × CH2-
CH3), and two 3H triplet each at 1.03-1.01 (CH3-CH2) and 
0.84-0.81 (CH3-CH2). This implies the presence of 
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(CH3CH2)2N-(C=O) as structural feature in (8g) which 
signified effective amidation of (7a).  
In like manner, the infrared stretching vibration band of 
N-H was observed at 3289 cm-1 and 3260 cm-1 for (7g) and 
(8g) respectively whereas the band at 1595 cm-1 depicted 
the presence of C=C of aromatic. The C=O of acid in (7g) 
appeared at 1711 cm-1 whereas, the same band shifted to 
1690 cm-1 in the compound (8g), indicating the conversion 
of acid functionality to amide group. The mass spectrum of 
(7g) showed peaks at m/z of 227.1 which represented loss 
of CO2 while its base peak at m/z 226.1 was as a result of 
loss of COOH. Its mass spectrum did not show molecular 
ion peak, probably because there could have been 
fragmentation before the molecule reached the detector. 
The mass spectrum of (7g) was also characterized by the 
occurrence of some daughter fragments at m/z 155.0, 92.1, 
91.1, 65.0 with relative intensities of 98%, 33%, 92% and 
48% respectively (Scheme 2).   
 
 
Scheme 1  Pathway for the synthesis of arylsulfonamide precursors (7a-k). 
 
Scheme 2  Proposed fragmentation pattern for mass spectrum of (7g). 
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Table 1 Conversion of p-toluenesulfonamide to N,N-diethylamido sulfonamide products. 
Entry p-Toluenesulfonamide Amidating Agent N,N-diethyl amide product 
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Biological Evaluation  
The antimicrobial sensitivity testing of the nineteen 
synthesized compounds were assayed using agar diffusion 
technique38. For the sake of brevity and better understanding,  
the selectivity index of the synthesized p-tolylsulfonamide 
derivatives on E. coli is as shown in Fig. 2. The selectivity 
index, which was evaluated by comparing the zone of 
inhibition (mm) obtained from each of the synthesized 
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compounds with that of clinical standard (streptomycin), 
gave a clearer picture of the antibacterial activity of this 
group of sulfonamides on the targeted organisms. Although, 
majority of the p-tolylsulfonamides have moderate to high 
activity, but none of them could compete with the 
streptomycin in E. coli growth inhibition efficacy. It was 
observable that the S.I. of p-tolylsulfonamide varied from 
0.5 for (7c) to 0.98 for (8j). Unequivocally speaking, 
streptomycin, with S.I. value of unity, demonstrated high 
level of superiority to all the synthesized p-
tolylsulfonamide on the inhibition of E. coli growth. The 
highest activity was observed in (8j) with S.I. of 0.98. This 
improved activity might be as a result of additional 
conjugation which occurred in (8j), other compounds that 
showed high activity include (7d), (7e), (7k), (8a), (8b), 
(8c), (8d) and (8g) (S.I. > 0.8). Within the class, it was 
noticeable that only seven compounds showed moderate 
activity, in a decreasing order (7f) ≈ (7g) > (7h) > (7j) > 
(7a) ≈ (7i) > (7b) (0.6 < S.I. < 0.8) while the least activity 
which was categorized by S.I. < 0.6, was experienced in 
one compound (7c) with S.I. value of 0.5 to be precised. 
In like manner, the antibacterial activity of p-
tolylsulfonamides with respect to streptomycin antibiotic 
on the S. aureus clinical isolate was also evaluated and 
pictorially presented as shown in Fig. 3. Based on the 
intensity of the selectivity index, (8j) could be considered 
as the most active (S.I. value = 1.6) while (7a) and (8g) 
were the least active having S.I. value of 0.47. It is worthy 
to note that two compounds (7f) and (8j) were more active 
than the streptomycin as far as S. aureus screening was 
concerned. All other p-tolylsulfonamides were less active 
than streptomycin except (7i), which in this case, competed 
favourably with the streptomycin standard. Hence, ten p-
tolylsulfonamides exhibited moderate activity on S. aureus 
in a decreasing order as (7k) > (7g) > (7d) ≈ (7e) ≈ (7h) ≈ 
(8a) > (7j) > (8c) ≈ (8b) > (8d) (0.5 < S.I. < 0.8) whereas 
lesser activity was exhibited by compounds (7c) > (7b) > 
(7a) ≈ (8g) (S.I. < 0.5).  
 
Fig. 2  Antibacterial activity of the synthesized compounds against Escherichia coli. 
 
Fig. 3  Antibacterial activity of p-tolylsulfonamides against Staphylococcus aureus. 
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Furthermore, in order to establish the lowest 
concentration at which the growth of E. coli and S. aureus 
was inhibited by p-tolylsulfonamide scaffolds, the MIC test 
was carried out according to a standard procedure39 and the 
result is as shown in Table 2. From the point of view of E. 
coli, the MIC values ranged from 12.5 μg/mL (8j) to 1000 
μg/mL (7c) while the MIC value for streptomycin under 
similar condition was 6.25 μg/mL. Although, streptomycin 
was more active than any of the p-tolylsulfonamides, it was 
apparent that different p-tolylsulfonamides exhibited 
varying MIC values against the strain of E. coli. Thus, the 
MIC values ranging from 12.5 μg/mL to 50 μg/mL was 
observable among (8j), (8d), (7k), (7d), (7e), (8a) and (8c); 
between 62.5 μg/mL and 100 μg/mL for (8b), (8g), (7f) and 
(7g); between 125 μg/mL and 500 μg/mL for (7a), (7b), 
(7i), (7h) and (7j) and the least activity was observed in 
compound (7c) with an MIC value of 1000 μg/mL.  
In addition, the MIC test for the series of p-
tolylsulfonamides was carried out on S. aureus (Table 2) 
and it should be noted that the lowest MIC value 
culminated into highest potency40. It is therefore paramount 
to note that the highest potency was observed in (8j) (MIC 
= 25 μg/mL) while compound (8g) exhibited the least 
potency (MIC = 1000 μg/mL) on S. aureus. This is higher 
activity than the one reported by Ghorab et al., (2004). 
From comparative study, many members of this group such 
as (7d) - (7k), (8a) and (8j) (MIC = 25 μg/mL – 100 μg/mL) 
were more active than streptomycin (MIC = 125 μg/mL) 
using the MIC test involving S. aureus. Under the same 
condition, (8b) (MIC = 125 μg/mL) competed favorably 
with streptomycin in its inhibitory potential on S. aureus. 
Seven compounds (7d), (7e), (7g), (7h), (7j), (7k) and (8a) 
had MIC value 100 μg/mL and other seven p-
tolylsulfonamides (8b), (8c), (8d), (7a), (7b), (7c) and (8g) 
had MIC values between 125 μg/mL and 1000 μg/mL.  
Furthermore, from the structure activity relationship 
(SAR) study, it was observed that the nature of side chains 
(R and R1-CH-R2) of the p-tolylsulfonamides (Scheme 1) 
and the presence of N,N-diethylated amido moieties 
{(CH3CH2)2N-C=O} of the amide (Table 1) contributed 
immensely toward synergistic or antagonistic effect on the 
reported in vitro antibacterial activity. For instance, 
regarding the trend of activity against E. coli, (8a) and (8g) 
were two times more active (7a) and (7g) respectively 
while (8b) was four times more active than (7b). In fact, 
(8c) was twenty times more active than (7c). The 
compounds (8a-8c), (8g) were structurally related with (7a-
7c), (7g), but the only disparity was the presence of N,N-
diethyl amide chain in the former, which probably 
accounted for their better activities than the latter.  
In view of these, there was a clear indication that 
presence of N,N-disubstituted amide led to an upward trend 
in the activity against E. coli. This was in agreement with 
earlier report that N,N-disubstituted thiosemicarbazones are 
more active than their mono- and non-substituted 
counterparts on S. aureus and E. coli35. Considering the 
effect of side chain, (8j) (R = Ph-CH2) was four times more 
active than the (8d) (R = H-CH2) on E. coli. This was as a 
result of π-π stack character introduced by the Ph group 
which is weakly activating in nature and the extensive 
conjugation contributed by C=C aromatic from the Ph in 
the case of (8j). In a similar manner, (8j) was ten times 
more active than (8d) on S. aureus. Synergistic 
contribution of N,N-diethyl amide caused (8b) and (8c) to 
be two times more active than (7b) and (7c) respectively on 
S. aureus. 
Table 2  MIC test of p-tolylsulfonamides on  
targeted organisms (μg/mL). 
Organisms→ 
Compd. No↓ 
E. coli ATCC 
25922 
S. aureus ATCC 
6538 
@100 
μg/mL 
@1000 
μg/mL 
@100 
μg/mL 
@1000
μg/mL 
(7a) >100 125 >100 250 
(7b) >100 250 >100 250 
(7c) >100 1000 >100 500 
(7d) 25 <1000 100 <1000 
(7e) 50 <1000 100 <1000 
(7f) 100 <1000 50 <1000 
(7g) 100 <1000 100 <1000 
(7h) >100 500 100 <1000 
(7i) >100 250 62.5 <1000 
(7j) >100 500 100 <1000 
(7k) 25 <1000 100 <1000 
(8a) 50 <1000 100 <1000 
(8b) 62.5 <1000 >100 125 
(8c) 50 <1000 >100 250 
(8d) 25 <1000 >100 250 
(8g) 62.5 <1000 >100 1000 
(8j) 12.5 <1000 25 <1000 
Str. 6.25 <1000 >100 125 
>100 means that if there was no growth inhibition at 
100 μg/mL, it was repeated at 1000 μg/mL, <1000 μg/mL 
means that growth inhibition has already been experienced 
at lower concentration less than or equal to 100 μg/mL; 
hence, there is no need to repeat the test at 1000 μg/mL. – 
means no activity was observed even at 1000 μg/mL. Str. 
means Streptomycin clinical reference.  
Conclusion 
Sulfonamide drugs which have brought about an antibiotic 
revolution in medicine are associated with a wide range of 
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biological activities. N,N-Diethylsubstituted amide bearing 
sulfonamides were herein successfully synthesized from p-
toluenesulfonamide precursors via non-conventional 
amidation approach. The antibacterial activity of the 
synthesized compounds was evaluated upon Escherichia 
coli and Staphylococcus aureus as the targeted organisms. 
N,N-Diethyl-2-(4-methylphenylsulfonamido)-3-phenylpropan- 
amide (8j) emerged as the most active antibacterial agents 
with MIC values of 12.5 μg/mL and 25 μg/mL on  E. coli 
and S. aureus respectively.  
Experimental 
General  
Melting points were determined on XT-4 digital 
microscopic melting point apparatus and were uncorrected. 
Infra red spectra were recorded as KBr disc on Varian 
Excalibur HE 3100 FT-IR Spectrometer while mass spectra 
were obtained using Waters GCT Premier Spectrometer. 
The 1H-NMR and 13C-NMR spectra were recorded in 
CDCl3 or DMSO-d6, unless otherwise stated, on NMR 
Bruker DPX 400 spectrometer operating at 400 MHz and 
100 MHz respectively (δ in ppm relative to Me4Si). The 
elemental analysis (C, H, N) of the synthesized compounds 
were performed using a Flash EA 1112 elemental analyzer. 
In addition, the pH was monitored and confirmed during 
acidification with a Portable pH Meter Model PHB4. All 
drying were conducted at reduced pressure with DHG-
9023A Vacuum Oven. Results were found to be in good 
agreement with the calculated values (Table 1). All 
compounds were routinely checked by TLC on silica gel G 
plates and column chromatographic purifications were 
carried out on Merck silica gel F (Mesh 200-300) using 
chloroform/ methanol (9:1, v/v) solvent system and the 
developed plates were visualized under UV light. All the 
amino acids used were obtained from Aladdin Chemical Co. 
Ltd. while p-toluenesulfonyl chloride was supplied by 
Huaxueshiji China. All other chemicals were obtained from 
Beijing Chemical Works, China. Solvents used were of 
analytical grade and, when necessary, were purified and 
dried by standard methods. 
General procedure for synthesis of  
p-toluenesulfonamides (7a-k) 
Na2CO3 (2.785 g, 26.25 mmol) was added to a solution of 
amino acid (12.5 mmol) in H2O (15 mL) at 0 oC followed 
by addition of p-toluenesulfonyl chloride, p-TsCl (2.86 g, 
15 mmol) in three portions over a period of 1 h. The slurry 
was then warmed to room temperature and allowed to stir 
for 4 h. Upon completion of the reaction which was TLC 
monitored using CHCl3/CH3OH solvent system (9:1), the 
reaction mixture was acidified with 20 % concentrated 
aqueous HCl solution to pH 2, after which crystallization 
occurred and the product was obtained via suction filtration. 
The filtered crude product was washed with pH 2.2 buffer 
and dried in a vacuum oven at 60 oC for 12 h to afford p-
toluenesulfonamides (7a-k) in good to excellent yields 
(60.5 – 99.0%).  
1-Tosylpyrrolidine-2-carboxylic acid (7a) 
Yield 3.23 g (95.9%), mp 41-43 oC, {Lit. mp 42-44 oC},34 
Rf = 0.82 (CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-
d6) δ: 7.72-7.70 (d, J = 8 Hz, 2H, Ar-H), 7.43-7.41 (d, J = 8 
Hz, 2H, Ar-H), 4.08-4.05 (m, 1H, CH-COOH), 3.36-3.30 
(m, 1H, CHb of CH2-N), 3.16-3.10 (m, 1H, CHa of CH2-N), 
2.39 (s, 3H, CH3), 1.89-1.77 (m, 3H, CH & CH2), 1.56-1.50 
(m, 1H, CH). 13C-NMR (DMSO-d6) δ: 173.2 (CO), 143.5, 
134.7, 129.9, 127.2, 67.1, 60.5, 48.5, 30.5, 25.2, 24.3, 21.1. 
IR (KBr) cm-1: 3217 (OH), 2939 (CH aromatic), 2860 (CH 
aliphatic), 1734 (C=O of COOH), 1601 (C=C aromatic), 
1184, 1151 (SO2 two bands), 662 (Ar-H).  
1-Tosylpiperidine-2-carboxylic acid (7b) 
Yield 3.36 g (95%), Rf = 0.89 (CHCl3/CH3OH, 9:1, at RT). 
1H-NMR (CDCl3) δ: 7.71-7.63 (d, J = 8 Hz, 2H, Ar-H), 
7.29-7.24 (d, J = 8 Hz, 2H, Ar-H), 4.74-4.73 (m, 1H, CH-
COOH), 3.72-3.69 (dd, J1 = 10.4 Hz, J2 = 20 Hz, 1H), 
3.23-3.18 (dd, J1 = 12 Hz, J2 = 20 Hz,  1H), 2.41 (s, 3H, 
CH3), 2.18-2.15 (dd, J1 = 3.7 Hz, J2 = 12.7 Hz, 1H), 1.74-
1.55 (m, 4H), 1.48-1.35 (m, 3H, CH2 & CH). 13C-NMR 
(DMSO-d6) δ: 171.8 (CO), 142.9, 137.4, 129.6, 129.4, 
126.9, 126.8, 54.6 (CH-CO), 42.1 (CH2-N), 27.0, 23.9, 
19.7 (CH2), 21.0 (CH3-Ph). MS: in m/z [rel. %]: 239.1 [M+ 
- CO2, 10%], 238.1 [M+ - COOH, 74%], 220.1 [37%], 
191.1 [M+ - PhCH2, 28%], 91.1 [PhCH2+, 100%]. Anal. 
calcd. for C13H17NO4S (283.35): C, 55.11; H, 6.05; N, 4.94. 
Found: C, 54.10; H, 6.08; N, 5.02.  
2-(4-Methylphenylsulfonamido)acetic acid (7c)  
Yield 2.75 g (95.8%), mp 145-146 oC, {Lit. mp 147 oC},41 
Rf = 0.47 (CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-
d6) δ: 12.63 (s-br, 1H, OH of -COOH), 7.95-7.92 (t, J = 6 
Hz, 1H, NH-CH2), 7.68-7.66 (d, J = 8 Hz, 2H, Ar-H), 7.38-
7.36 (d, J = 8 Hz, 2H, Ar-H), 3.55-3.53 (d, J = 6 Hz, 2H, 
CH2-NH), 2.37 (s, 3H, CH3). IR (KBr) cm-1: 3279 (N-H), 
3102 (CH aromatic), 2980 (CH aliphatic), 1726 (C=O of 
COOH), 1595 (C=C aromatic), 1234, 1161 (SO2 two 
bands), 669 (Ar-H). MS: in m/z [rel. %]: 238.1 [41%], 
184.0 [55%], 155.0 [PhCH2SO2+, 100%], 91.1 [PhCH2+, 
65%], 65.0 [63%].    
2-(4-Methylphenylsulfonamido)propanoic acid (7d)  
Yield 2.51 g (82.6%), mp 116-118 oC, Rf = 0.78 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-d6) δ: 8.05-
8.03 (d, J = 8.3 Hz, 1H, NH), 7.68-7.65 (d, J = 8 Hz, 2H, 
Ar-H), 7.37-7.35 (d, J = 8 Hz, 2H, Ar-H), 3.74-3.71 (m, 1H, 
CH), 2.37 (s, 3H, CH3-Ph), 1.13-1.12 (d, J = 7.2 Hz, 3H, 
CH3-CH). IR (KBr) cm-1: 3277 (N-H), 3084 (OH), 2934 
(CH aliphatic), 1715 (C=O of COOH), 1595 (C=C 
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aromatic), 1233, 1150 (SO2 two bands), 677 (Ar-H). MS: in 
m/z [rel. %]: 199.1 [M+ - CO2, 12%], 198.0 [M+ - CO2H, 
89%], 156.0 [CH3PhSO2+, 21%], 155.0 [PhCH2SO2+, 97%], 
91.1 [PhCH2+, 100%], 65.0 [47%], 44.1 [27%].    
3-Mercapto-2-(4-methylphenylsulfonamido) 
propanoic acid (7e)  
Yield 3.03 g (88.1%), mp 161-164 oC, Rf = 0.39 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-d6) δ: 8.59-
8.53 (s-br, 1H, SH), 8.29-8.27 (d, J = 8.4 Hz, 1H, NH-CH), 
7.71-7.69 (m, 1H, CH2-CH-NH), 7.65-7.58 (d, J = 8 Hz, 
2H, Ar-H), 7.48-7.46 (d, J = 7.6 Hz, 1H, CHb of CH2), 
7.35-7.33 (d, J = 8 Hz, 2H, Ar-H), 7.12-7.10 (d, J = 7.6 Hz, 
1H, CHa of CH2), 2.37 (s, 3H, CH3-Ph). IR (KBr) cm-1: 
3445 (N-H), 3003 (CH aromatic), 2907 (CH aliphatic), 
1736 (C=O of COOH), 1596 (C=C aromatic), 1221, 1152 
(SO2 two bands), 679 (Ar-H).   
2-(4-Methylphenylsulfonamido)-4-(methylthio) 
butanoic acid (7f)  
Yield 2.62 g (69.1%), mp 105-106 oC, Rf = 0.80 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 7.75-
7.73 (d, J = 8 Hz, 2H, Ar-H), 7.29-7.27 (d, J = 8 Hz, 2H, 
Ar-H), 4.07 (s-br, 1H, NH), 2.50-2.48 (m, 1H, CH-NH), 
2.45-2.33 (m, 2H, CH2-S), 2.40 (s, 3H, CH3-Ph), 2.10-2.03 
(m, 1H, CH of CH2), 1.99 (s, 3H, CH3-S), 1.94-1.87 (m, 1H, 
CH of CH2). IR (KBr) cm-1: 2997 (CH aromatic), 2911 
(CH aliphatic), 1726 (C=O of COOH), 1591 (C=C 
aromatic), 1220, 1144 (SO2 two bands), 696 (Ar-H).    
3-Methyl-2-(4-methylphenylsulfonamido) 
butanoic acid (7g).  
Yield 3.21 g (94.7%), mp 125-126 oC, Rf = 0.81 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 7.73-
7.71 (d, J = 8 Hz, 2H, Ar-H), 7.29-7.27 (d, J = 8 Hz, 2H, 
Ar-H), 5.07-5.04 (d, J = 9.9 Hz, 1H, NH), 3.82-3.78 (dd, J1 
= 4.6 Hz, J2 = 9.9 Hz, 1H, CH-CH-NH), 2.41 (s, 3H, CH3-
Ph), 2.13-2.08 (m, 1H, CH), 0.97-0.96 (d, J = 6.8 Hz, 3H, 
CH3), 0.88-0.86 (d, J = 6.8 Hz, 3H, CH3). IR (KBr) cm-1: 
3289 (N-H), 2967 (CH aromatic), 2876 (CH aliphatic), 
1711 (C=O of COOH), 1595 (C=C aromatic), 1335, 1163 
(SO2 two bands), 687 (Ar-H). MS: in m/z [rel. %]: 227.1 
[M+ - CO2, 11%], 226.1 [M+ - CO2H, 100%], 155.0 
[PhCH2SO2+, 98%], 92.1 [PhCH3+, 33%], 91.1 [PhCH2+, 
92%], 65.0 [48%], 44.0 [CH2(CH3)2+, 14%]. Anal. calcd. 
for C12H17NO4S (271.34): C, 53.12; H, 6.32; N, 5.16. 
Found: C, 52.91; H, 6.33; N, 5.08. 
3-Hydroxy-2-(4-methylphenylsulfonamido) 
butanoic acid (7h).  
Yield 3.22 g (94.4%), mp 90-92 oC, Rf = 0.62 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-d6) δ: 7.68-
7.66 (d, J = 8 Hz, 2H, Ar-H), 7.52-7.50 (d, J = 9.2 Hz, 1H, 
NH-CH), 7.34-7.32 (d, J = 8 Hz, 2H, Ar-H), 3.95-3.91 (m, 
1H, CH), 3.64-3.61 (dd, J1 = 3.6 Hz, J2 = 9.2 Hz, 1H, CH-
CH-NH), 2.36 (s, 3H, CH3-Ph), 2.08 (s, 1H, -OH), 1.01-
0.99 (d, J = 6.36 Hz, 3H, CH3-CH). IR (KBr) cm-1: 3501 
(OH free), 3435 (N-H), 3360 (OH of COOH), 3262 (N-H), 
2976 (CH aliphatic), 1697 (C=O), 1595 (C=C aromatic), 
1167 (SO2), 673 (Ar-H).   
5-Amino-2-(4-methylphenylsulfonamido)-5- 
oxopentanoic acid (7i).  
Yield 3.10 g (82.7%), mp 145-146 oC, Rf = 0.14 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-d6) δ: 8.06-
8.04 (d, J = 8.76 Hz, 1H, NH-CH), 7.65-7.63 (d, J = 8 Hz, 
2H, Ar-H), 7.36-7.34 (d, J = 8 Hz, 2H, Ar-H), 7.24 (s, 1H, 
NH of NH2), 6.73 (s, 1H, NH of NH2), 3.69-3.65 (dd, J1 = 
8.76 Hz, J2 = 17.24 Hz, 1H, CH-COOH), 2.37 (s, 3H, CH3-
Ph), 2.08-2.04 (t, J = 7.68 Hz, 2H, CH2), 1.83-1.80 (t, J = 4 
Hz, 1H, CH), 1.67-1.61 (q, J1 = 4 Hz, J2 = 7.6 Hz, CH). IR 
(KBr) cm-1: 3456 (N-H), 3331 (OH of COOH), 3246 (N-H), 
2955 (CH aliphatic), 1678 (C=O), 1640 (C=O), 1570 (C=C 
aromatic), 1321, 1167 (SO2 two bands), 685 (Ar-H). MS: in 
m/z [rel. %]: 246.0 [97%], 238.1 [16%], 171.0 
[CH3PhSO2NH2+, 49%], 156.0 [CH3PhSO2+, 84%], 139.0 
[52%], 123.0 [100%], 92.1 [PhCH3+, 38%], 44.0 [CONH2+, 
32%]. Anal. calcd. for C12H16N2O5S (300.34): C, 47.99; H, 
5.37; N, 9.33. Found: C, 47.77; H, 5.39; N, 9.04.  
2-(4-Methylphenylsulfonamido)-3- 
phenylpropanoic acid (7j)  
Yield 3.95 g (99.0%), 159-160 oC {Lit. mp 161 oC},41 Rf = 
0.76 (CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 
7.61-7.59 (d, J = 8 Hz, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H), 
7.10-7.08 (d, J = 8 Hz, 2H, Ar-H), 5.16-5.14 (d, J = 8.64 
Hz, 1H, NH), 4.22-4.17 (ddd, J1 = 5.6 Hz, J2 = 6.4 Hz, J3 = 
8.64 Hz, 1H, CH-COOH), 3.12-3.08 (dd, J1 = 5.6 Hz, J2 = 
20 Hz, 1H), 3.03-2.98 (dd, J1 = 6.4 Hz, J2 = 20 Hz, 1H), 
2.40 (s, 3H, CH3). 13C-NMR (CDCl3) δ: 175 (CO), 143.9, 
136.6, 134.9, 129.8 (2CH aromatic), 129.6 (2CH aromatic), 
128.8 (2CH aromatic), 127.5, 127.2 (2CH aromatic), 56.5, 
39.0 (CH2), 21.7 (CH3). IR (KBr) cm-1: 3350 (N-H), 3188 
(OH), 3057 (CH aromatic), 2961 (CH aliphatic), 1736 
(C=O of COOH), 1350, 1171 (SO2 two bands), 675 (Ar-H).   
2-(4-Methylphenylsulfonamido)-3-(4-(tosyloxy)phenyl) 
propanoic acid (7k)  
Yield 3.70 g (60.5%), mp 101-103 oC, Rf = 0.76 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 7.69-
7.67 (d, J = 8.26 Hz, 2H, Ar-H of OTs), 7.59-7.57 (d, J = 
8.26 Hz, 2H, Ar-H of OTs), 7.32-7.30 (d, J = 8 Hz, 2H, Ar-
H), 7.24-7.22 (d, J = 8 Hz, 2H, Ar-H), 7.03-7.01 (d, J = 8.4 
Hz, 2H, Ar-H of benzyl), 6.85-6.83 (d, J = 8.4 Hz, 2H, Ar-
H of benzyl), 5.14-5.12 (d, J = 8.5 Hz, 1H, NH-CH), 4.17-
4.12 (q, J = 6.8 Hz, 1H, NH-CH-CH2), 3.11-3.06 (dd, J1 = 
5.2 Hz, J2 = 20 Hz, 1H, CH of CH2-Ar), 2.97-2.92 (dd, J1 = 
6.8 Hz, J2 = 20 Hz, 1H, CH of CH2-Ar), 2.45 (s, 3H, CH3-
OTs), 2.41 (s, 3H, CH3-Ph). 13C-NMR (CDCl3) δ: 173.9 
(CO), 148.9, 145.7, 144.2, 136.4, 134.3, 132.4 (six benzylic 
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aromatic carbon atoms), 130.9, 130.9, 130.0, 130.0, 129.9, 
129.9, 128.6, 128.6, 127.2, 127.2, 122.6, 122.6 (twelve 
sulfonyl aromatic carbon atoms), 56.4 (CH), 38.3 (benzylic 
CH2), 21.9 (CH3 linked to SO3-Ar), 21.7 (CH3 linked to 
SO2-Ar). IR (KBr) cm-1: 3561 (N-H), 3339 (OH of COOH), 
2924 (CH aliphatic), 1717 (C=O), 1559 (C=C aromatic), 
1150, 1092 (SO2 two bands), 669 (Ar-H). MS: in m/z 
[rel. %]: 443.1 [M+ - COOH, 23%], 171.0 [CH3PhSO2NH2+, 
35%], 156.0 [CH3PhSO2+, 58%], 155.0 [PhCH2SO2+, 90%], 
134.1 [90%], 92.1 [PhCH3+, 64%], 65.0 [100%]. Anal. 
calcd. for C23H23NO7S2 (489.57): C, 56.43; H, 4.74; N, 2.86. 
Found: C, 54.16; H, 4.79; N, 5.31. 
General procedure for N,N-diethylalkanamide of  
p-toluenesulfonamide (8a-k) 
A three-necked 250 mL flask equipped with magnetic 
stirring bar was charged with appropriate p-
toluenesulfonamide (7a-k) (2.96 mmol) and 
dichloromethane (DCM) (10 mL). The flask was stoppered, 
cooled to 0 oC and N2 was bubbled into it continuously. 
Oxalyl chloride (0.34 mL, 3.85 mmol, 1.3 equiv.) was 
added via dropping pipette to maintain the temperature 
below 10 oC followed by the addition of 2 drops of 
dimethyl formamide (DMF). The resulting mixture was 
stirred at room temperature until the conversion to acid 
chloride was completed (i.e. for about 1.5 h) and then 
concentrated to dryness with rotary evaporator (23 oC, 40 
mmHg). Dichloromethane (DCM) (20 mL) was added to 
the resulting crude acid chloride and the solution was 
concentrated again.  
In a separate 250 mL three-necked round bottom flask, 
equipped with a magnetic stirring bar, a N2 inlet, a rubber 
septum, 125-mL pressure equalizing addition funnel and a 
temperature probe was charged with dichloromethane 
(DCM) (10 mL), triethylamine (0.62 mL, 4.44 mmol, 1.5 
equiv.) and diethylamine (0.4 mL, 3.85 mmol, 1.3 equiv.) 
and the mixture was cooled to -10 oC (acetone/ice bath). 
The crude acid chloride was dissolved in dichloromethane 
(DCM) (10 mL) and this solution was transferred to the 
addition funnel. The acid chloride was then added 
dropwisely to the stirred diethylamine solution at such a 
rate that the internal temperature was maintained below 10 
oC. Upon completion of the addition of the acid chloride 
solution (ca 30 min), the mixture was stirred at -10 to 0 oC 
for 1 h and at room temperature for 1 h.  
The mixture was then diluted with 2M HCl (6 mL) and 
was transferred into a 250 mL separatory funnel and the 
layers separated. The organic layer was washed with brine 
(6 mL) and was then concentrated under reduced pressure 
(23 oC, 40 mmHg), diluted with methanol (6 mL) and re-
concentrated to give a crude solid. The solid was slurried in 
methanol (7.5 mL) and water (15 mL) was added dropwise 
with continuous stirring for 10 min. The slurry was stirred 
at room temperature for 1 h and allowed to crystallize 
according to Kuethe and Beutner, method [37]. It was 
filtered by suction and dried under vacuum/N2 sweep for 8 
h to afford N,N-diethyl substituted p-tolylsulfonamides (8a-
k). 
N,N-Diethyl-1-tosylpyrrolidine-2-carboxamide (8a)  
Yield 0.89 g (92.3%), mp 114-116 oC, 1H-NMR (CDCl3) δ: 
7.76-7.73 (m, 2H, Ar-H), 7.33-7.31 (d, J = 8.0 Hz, 1H, Ar-
H), 7.28-7.26 (d, J = 8.0 Hz, 1H, Ar-H), 4.73-4.70 (m, 1H, 
CHa of CH2-N), 4.26-4.24 (m, 1H, CHb of CH2-N), 3.50-
3.41 (m, 2H, CH2-CH3), 3.34-3.29 (m, 2H, CH2-CH3), 
2.42-2.39 (d, J = 12.12 Hz, 3H, CH3), 2.11-2.09 (m, 2H, 
CH2 of pyrrolo), 1.94-1.71 (m, 3H, CH2 & CH of pyrrolo), 
1.27-1.23 (t, J = 7.2 Hz, 3H, CH3-CH2), 1.09-1.06 (t, J = 
7.12 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 2974 (aromatic), 
2866 (CH aliphatic), 1657 (C=O), 1609 (C=C aromatic), 
1149, 1107 (SO2 two bands), 673 (Ar-H). MS: in m/z 
[rel. %]: 225.0 [MH+ - CON(CH2CH3)2, 62%], 224.0 [M+ - 
CON(CH2CH3)2, 100%], 169.1 [89%], 155.0 [PhCH2SO2+, 
93%], 100.1 [+CON(CH2CH3)2, 17%], 91.0 [PhCH2+, 82%], 
72.0 [45%], 65.0 [42%]. Anal. calcd. for C16H24N2O3S 
(324.45): C, 59.23; H, 7.46; N, 8.63. Found: C, 57.97; H, 
7.20; N, 7.92. 
N,N-Diethyl-1-tosylpiperidine-2-carboxamide (8b)  
Yield 0.94 g (94.1%), mp 127-129 oC, 1H-NMR (CDCl3) δ: 
7.58-7.56 (d, J = 8.0 Hz, 2H, Ar-H), 7.21-7.19 (d, J = 8.0 
Hz, 2H, Ar-H), 4.86-4.85 (m, 1H, CH-COOH), 3.73-3.70 
(q, J = 7.2 Hz, 2H, CH2-CH3), 3.31-3.26 (q, J = 7.08 Hz, 
2H, CH2-CH3), 3.15-3.14 (m, 1H, CHa of CH2-N), 3.09-
3.08 (m, 1H, CHb of CH2-N), 2.36 (s, 3H, CH3), 1.75-1.66 
(m, 3H, CH & CH2 of piperidine), 1.59-1.50 (m, 3H, CH & 
CH2 of piperidine), 1.26-1.23 (t, J = 7.2 Hz, 3H, CH3-CH2), 
0.96-0.93 (t, J = 7.02 Hz, 3H, CH3-CH2). Anal. calcd. for 
C17H26N2O3S (338.47): C, 60.33; H, 7.74; N, 8.28. Found: 
C, 60.27; H, 7.60; N, 8.32. 
N,N-Diethyl-2-(4-methylphenylsulfonamido) 
acetamide (8c)  
Yield 0.69 g (82.7%), mp 109-111 oC, 1H-NMR (CDCl3) δ: 
7.75-7.73 (d, J = 8.0 Hz, 2H, Ar-H), 7.29-7.27 (d, J = 8.0 
Hz, 2H, Ar-H), 5.80 (s-br, 1H, NH), 3.73-3.72 (d, J = 4.12 
Hz, 2H, CH2-NH), 3.31-3.26 (q, J = 7.14 Hz, 2H, CH2-
CH3), 3.17-3.11 (q, J = 7.18 Hz, 2H, CH2-CH3), 2.40 (s, 3H, 
CH3-Ar), 1.12-1.08 (t, J = 7.18 Hz, 3H, CH3-CH2), 1.02-
0.99 (t, J = 7.14 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 3034 
(CH aromatic), 2946 (CH aliphatic), 1707 (C=O), 1601 
(C=C aromatic), 1191, 1145 (SO2 two bands), 694 (Ar-H). 
Anal. calcd. for C13H20N2O3S (284.38): C, 54.91; H, 7.09; 
N, 9.85. Found: C, 55.03; H, 7.13; N, 9.92. 
N,N-Diethyl-2-(4-methylphenylsulfonamido) 
propanamide (8d)  
Yield 0.68 g (77.9%), mp 121-124 oC, 1H-NMR (CDCl3) δ: 
7.74-7.66 (m, 2H, Ar-H), 7.28-7.22 (m, 2H, Ar-H), 5.46-
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5.44 (d, J = 8.48 Hz, 1H, NH-CH), 4.25-4.15 (m, 1H, NH-
CH-CH3), 3.99-3.92 (q, J = 7.12 Hz, 4H, 2 × CH2-CH3), 
2.38 (s, 3H, CH3-Ar), 1.39-1.37 (d, J = 7.16 Hz, 3H, CH3-
CH), 1.13-1.09 (t, J = 7.12 Hz, 6H, 2 × CH3-CH2). IR (KBr) 
cm-1: 3279 (N-H), 3107 (CH aromatic), 1711 (C=O), 1620 
(C=C aromatic), 1225, 1152 (SO2 two bands), 677 (Ar-H). 
Anal. calcd. for C14H22N2O3S (298.41): C, 56.35; H, 7.43; 
N, 9.39. Found: C, 56.42; H, 7.35; N, 9.44. 
N,N-Diethyl-3-methyl-2-(4-methylphenylsulfonamido) 
butanamide (8g)  
Yield 0.86 g (89.1%), mp 164-166 oC, 1H-NMR (CDCl3) δ: 
7.68-7.66 (d, J = 8.0 Hz, 2H, Ar-H), 7.23-7.21 (d, J = 8.0 
Hz, 2H, Ar-H), 5.78-5.75 (d, J = 9.24 Hz, 1H, NH-CH), 
3.81-3.78 (dd, J1 = 4.22 Hz, J2 = 9.24 Hz, 1H, NH-CH-CH), 
3.15-3.02 (m, 4H, 2xCH2-CH3), 2.37 (s, 3H, CH3-Ar), 
1.83-1.78 (m, 1H, CH-CH(CH3)2), 1.03-1.01 (d, J = 6.8 Hz, 
3H, CH3-CH), 0.92-0.88 (t, J = 7.2 Hz, 3H, CH3-CH2), 
0.84-0.82 (d, J = 6.0 Hz, 3H, CH3-CH), 0.84-0.81 (t, J = 
6.48 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 3260 (N-H), 2974 
(CH aliphatic), 1668 (C=O), 1167, 1090 (SO2 two bands), 
689 (Ar-H). Anal. calcd. for C16H26N2O3S (326.46): C, 
58.87; H, 8.03; N, 8.58. Found: C, 58.79; H, 7.98; N, 8.59. 
N,N-Diethyl-2-(4-methylphenylsulfonamido)-3-
phenylpropanamide (8j)  
Yield 0.99 g (89.4%), mp 169-170 oC, 1H-NMR (CDCl3) δ: 
7.67-7.65 (d, J = 8.0 Hz, 2H, Ar-H), 7.24-7.19 (m, 5H, Ar-
H), 7.13-7.09 (m, 2H, Ar-H), 5.88-5.86 (d, J = 9.48 Hz, 1H, 
NH-CH), 4.31-4.25 (m, 1H, CH), 3.21-3.15 (m, 1H, CHa 
of CH2-Ph), 2.99-2.96 (m, 1H, CHb of CH2-Ph), 2.94-2.90 
(m, 2H, CH2-CH3), 2.80-2.74 (q, J = 7.2 Hz, 2H, CH2-CH3), 
2.37 (s, 3H, CH3-Ar), 0.88-0.84 (t, J = 7.14 Hz, 3H, CH3-
CH2), 0.84-0.81 (t, J = 7.2 Hz, 3H, CH3-CH2). IR (KBr) 
cm-1: 3306 (N-H), 2947 (CH aliphatic), 1710 (C=O), 1601 
(C=C aromatic), 1213, 1171 (SO2 two bands), 685 (Ar-H). 
Anal. calcd. for C20H26N2O3S (374.51): C, 64.14; H, 7.00; 
N, 7.48. Found: C, 64.07; H, 6.91; N, 7.63. 
Antibacterial Activity Assays 
The antimicrobial properties of the sulfonamides were 
investigated in form of the general sensitivity testing38 and 
minimum inhibitory concentration (MIC)39 with respect to 
freshly cultured targeted organisms. The two organisms of 
interest in this present study are one gram positive 
(Staphylococcus aureus ATCC 6538) and one gram 
negative (Escherichia coli ATCC 25922) organisms which 
are associated with the gastrointestinal tract damage in man 
and animal.  
Preparation of the inoculum 
The standard strains of S. aureus and E. coli used were 
obtained from Test Center of Antimicrobial Materials, 
TIPC, Beijing. No clinically isolated organism was used 
based on in-availability of such as at the time of this study. 
The strains were propagated on nutrient agar plates and 
maintained on the plate at 4 oC. The isolates were sub-
cultured in nutrient broth at 37 oC for 8 h prior to 
antibacterial testing. 
Antibacterial sensitivity testing of the  
synthesized compounds 
Agar well diffusion technique as described by Adeniyi and 
co-workers was used to determine the antibacterial activity 
of the synthesized compounds38. Sensitivity test agar plates 
were seeded with 0.1 mL of an overnight culture of each 
bacterial strain (equivalent to 107 – 108 CFU mL-1). The 
seeded plates were allowed to set and a standard cork borer 
of 8 mm diameter was used to cut uniform wells on the 
surface of the agar. The wells were then filled with 0.3 mL 
of each sulfonamide solution in appropriate solvent at a 
concentration of 1000 μg/mL (0.02g of sulfonamide 
dissolved in 20 mL DMSO). All the plates were incubated 
at 37 oC for 24 h. The assay was conducted at regular 
intervals of 24 h until marked decline in the potency of the 
sulfonamide solution to inhibit the growth of the test 
organisms was noticed. Zones of clearance round each well 
means inhibition and the diameter of such zones were 
measured. The procedure was repeated for the streptomycin 
(standard). 
Determination of minimum inhibitory  
concentration (MIC) 
Agar well dilution method as described by Russell and Furr 
was used to determine the minimum inhibitory 
concentration (MIC) of the sulfonamides and 
streptomycin39. Different dilutions of the sulfonamides 
were prepared first at ≤ 100 μg/mL to give final 
concentrations in the range of 100, 50, 25, 12.5 and 6.25 
μg/mL. The different dilutions of sulfonamide derivatives 
that could not inhibit the microbial growth at ≤ 100 μg/mL 
were later prepared at ≤ 1000 μg/mL to give final 
concentrations in the range of 1000, 500, 250, 125, 62.5 
μg/mL. Two milliliter (2 mL) of each dilution was mixed 
with 18 mL of Mueller Hinton agar (MHA, Difco, France) 
and poured into Petri-dishes and allowed to set. The agar 
was streaked with an overnight broth culture of the 
bacterial strains and incubated overnight. The plates were 
then examined for the presence or absence of growth. The 
minimum concentration that completely inhibited 
macroscopic growth was regarded as the minimum 
inhibitory concentration of the respective sulfonamide. The 
procedure was repeated for streptomycin (standard). 
Selectivity index (S.I.) is the ratio of zone of inhibition of 
compound to that of the streptomycin. 
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